Healthcare provider profile · identity verified

John Mark Ryan, M.D.

Internal Medicine · PROVIDENCE, RI · NPI 1841230968

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	608	156
Lisinopril	Lisinopril	406	104
Omeprazole	Omeprazole	343	84
Losartan Potassium	Losartan Potassium	319	82
Amlodipine Besylate	Amlodipine Besylate	226	60
Levothyroxine Sodium	Levothyroxine Sodium	184	50
Fluticasone Propionate	Fluticasone Propionate	181	72
Montelukast Sodium	Montelukast Sodium	179	45
Hydrochlorothiazide	Hydrochlorothiazide	177	56
Eliquis	Apixaban	146	28
Metformin Hcl	Metformin Hcl	140	32
Metformin Hcl Er	Metformin Hcl	139	34
Lorazepam	Lorazepam	135	26
Tamsulosin Hcl	Tamsulosin Hcl	120	33
Simvastatin	Simvastatin	114	27
Celecoxib	Celecoxib	112	18
Citalopram Hbr	Citalopram Hydrobromide	106	23
Jardiance	Empagliflozin	101	14
Meloxicam	Meloxicam	100	28
Metoprolol Succinate	Metoprolol Succinate	96	24
Famotidine	Famotidine	94	25
Sertraline Hcl	Sertraline Hcl	93	23
Metoprolol Tartrate	Metoprolol Tartrate	92	23
Atenolol	Atenolol	85	20
Clonazepam	Clonazepam	81	15
Albuterol Sulfate Hfa	Albuterol Sulfate	80	24
Pantoprazole Sodium	Pantoprazole Sodium	80	22
Trazodone Hcl	Trazodone Hcl	76	21
Gabapentin	Gabapentin	74	16
Rosuvastatin Calcium	Rosuvastatin Calcium	72	23
Finasteride	Finasteride	71	14
Duloxetine Hcl	Duloxetine Hcl	69	19
Pravastatin Sodium	Pravastatin Sodium	66	15
Furosemide	Furosemide	61	21
Mirtazapine	Mirtazapine	57	14
Chlorthalidone	Chlorthalidone	56	14
Xarelto	Rivaroxaban	51	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	49	suppressed
Ibuprofen	Ibuprofen	48	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	46	suppressed
Topiramate	Topiramate	46	11
Alendronate Sodium	Alendronate Sodium	45	suppressed
Glimepiride	Glimepiride	44	suppressed
Allopurinol	Allopurinol	43	11
Ozempic	Semaglutide	43	suppressed
Prednisone	Prednisone	43	34
Spironolactone	Spironolactone	41	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	40	suppressed
Warfarin Sodium	Warfarin Sodium	40	suppressed
Methocarbamol	Methocarbamol	37	12
Zolpidem Tartrate	Zolpidem Tartrate	37	suppressed
Lovastatin	Lovastatin	35	suppressed
Trulicity	Dulaglutide	35	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	34	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	suppressed
Potassium Chloride	Potassium Chloride	33	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	33	suppressed
Levetiracetam	Levetiracetam	32	suppressed
Valsartan	Valsartan	32	suppressed
Butalbital-Aspirin-Caffeine	Butalbital/Aspirin/Caffeine	31	suppressed
Tizanidine Hcl	Tizanidine Hcl	31	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Terazosin Hcl	Terazosin Hcl	30	suppressed
Tramadol Hcl	Tramadol Hcl	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	suppressed
Mounjaro	Tirzepatide	26	suppressed
Enalapril Maleate	Enalapril Maleate	25	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	19
Alprazolam	Alprazolam	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	16
Baclofen	Baclofen	20	suppressed
Colchicine	Colchicine	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Cefuroxime	Cefuroxime Axetil	19	18
Synthroid	Levothyroxine Sodium	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	12
Fluticasone Propionate Hfa	Fluticasone Propionate	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Diazepam	Diazepam	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Piroxicam	Piroxicam	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Dutasteride-Tamsulosin	Dutasteride/Tamsulosin Hcl	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Febuxostat	Febuxostat	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error